LAURA was a phase 3, randomized placebo-controlled trial evaluating adjuvant osimertinib until progression or death versus placebo among patients with NSCLC and an exon 19 or 21 EGFR mutation, who completed definitive chemo-RT (concurrent or sequential).8 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.